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Objectives: To investigate the characteristics and one-year outcomes following sirolimus-eluting CYPHER Select
Plus stent (SES) implantation in small (SmVD) and non-small vessel disease (NSmVD) in the international
e-SELECT registry.
Background: Large-scale registry data are lacking on DES outcomes in SmVD treatment.
Methods: There were 4,700 SmVD (at least one vessel with estimated reference vessel diameter [RVD] < 2.5 mm,
excluding 283 patients with unknown RVD vessels) and 10,139 NSmVD only patients.
Results: The SmVD population was older, with more women, diabetics, and vessels treated, higher mean Charlson
Comorbidity Index score (CCI), shorter lesions, and less STEMI presentation. The 1-year stent thrombosis (ST)
rate (primary end-point), was signiﬁcantly higher (1.3% vs. 0.7%) in SmVD versus NSmVD, mainly driven by
early events. One-year major adverse cardiac event (MACE), myocardial infarction (MI), and clinically indicated
target-lesion revascularization (TLR) rates were signiﬁcantly higher in SmVD although death and major bleeding
rates were similar in both groups. Complication rates were similar between pure (3,188 patients; only RVD <
2.5 mm) and mixed (1,795 patients; some RVD < 2.5 mm or unknown RVD) SmVD. Multivariate predictors for
1-year MACE in SmVD included saphenous vein graft or bifurcation lesions, major bleeding, any antiplatelet
therapy discontinuation within 1 month, age, number of stents implanted, CCI, acute coronary syndrome, and
insulin-dependent diabetes mellitus.
Conclusion: SES implantation for SmVD occurs more frequently in women, diabetics, and those with multivessel
disease and comorbidities. One-year ST, MACE, MI, and clinically indicated TLR rates are higher, although
low overall, in SmVD or mixed SmVD patients while death rates are similar to NSmVD. (J Interven Cardiol
2012;**:1–10)
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Introduction
From approximately one-third to over one-half of
percutaneous coronary intervention (PCI) is targeted at
signiﬁcant disease in small coronary artery segments,
deﬁned as those with estimated reference vessel diam-
eter (RVD) under a threshold ranging from 2.5 mm to
3 mm depending on the study.1–5 PCI of small coro-
nary artery segments, relative to that of larger caliber
vessels, is signiﬁcantly and directly associated with an
increased risk of major adverse cardiovascular events
(MACE), including restenosis and stent thrombosis
(ST).6–9 Some studies have reported higher rates of tar-
get vessel revascularization in small compared to large
vessels even with comparable postprocedural minimal
in-stent lumen areas, which could be a consequence of
the greater proportions of higher risk baseline clinical
and lesion characteristics, including diabetes,multives-
sel disease (MVD), diffuse disease, and chronic total
occlusion, among patients with small-vessel disease
(SmVD).1,10 The clinical relevance and management,
including medical therapy, PCI, and coronary artery
bypass graft surgery (CABG) of SmVD is inﬂuenced
by lesion location, amount of myocardium at risk, and
occlusion severity.11 CABG for revascularization of
small coronary vessels is limited by high rates of tech-
nical failure.12 For PCI of SmVD, various devices and
techniques have been used over time; however, it was
not until the introduction of drug-eluting stents (DES)
that outcomes in this challenging higher-risk setting
were greatly improved,1,2,13–25 likely because, com-
pared with large vessels, small vessels have a smaller
postprocedural luminal area that is less able to ac-
commodate neointimal hyperplasia.25,26 Data on large
“real-world” experienceswith PCI of SmVDhave been
lacking and therefore this study is aimed at investigat-
ing the characteristics and 1-year outcomes and predic-
tors of MACE following sirolimus-eluting CYPHER
stent (SES, Cordis Corporation, Johnson and Johnson,
Bridgewater, NJ, USA) implantation in SmVD relative
to those in non-SmVD (NSmVD) in the international
e-SELECT registry,whichwas conducted in 320 hospi-
tals throughout 56 countries, recruited 15,147 patients,
and was on the scientiﬁc advisory board of Cordis. Dr Gao has re-
ceived research supports from Abbott Vascular, Boston Scientiﬁc,
Medtronic, B Braun, and MicroPort Medical (Shanghai, China).
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and has been the subject of 5 publications focused on
different clinical subsets.27–31
Methods
The design, execution, and data analysis of the e-
SELECT registry has been previously described.27–31
The e-SELECT registry included 320 medical centers
in 56 countries. Baseline data were collected between
May 2006 and April 2008 in consecutive and eligible
patients who underwent implantation of ≥1 CYPHER
Select Plus (Cordis Corporation, Johnson and John-
son, Bridgewater, NJ, USA) SES according to standard
practice and procedural techniques. The protocol spec-
iﬁed very few inclusion or exclusion criteria. Although
lesions could be pretreated with any technique or de-
vice (such as balloon angioplasty, cutting balloon, or
atherectomy), implantation of SES in each target lesion
during index procedure was mandatory. All postoper-
ative medical management, including antithrombotic
therapy, was prescribed according to usual local prac-
tice. The protocol was approved by the ethics com-
mittee of each participating medical center, and the pa-
tients granted their consent to participate in the registry.
Patients for whom the collection of dependable follow-
up information was unlikely and those who received a
stent other than a CYPHER SES during the index pro-
cedure were excluded. RVD was visually estimated by
angiography, and small vessels were deﬁned as those
with an RVD ≤ 2.5 mm. The primary end-point of the
registry was a composite of deﬁnite and probable ST
at 1 year of follow-up, as deﬁned by the Academic Re-
search Consortium.32 Secondary end-points at 1 year
included rates of major bleeding (MB) according to
the STEEPLE (Safety and efﬁcacy of Enoxaparin in
PCI) deﬁnition,33 cardiac and noncardiac death, my-
ocardial infarction (MI), and MACE (deﬁned as any
death, MI, or target lesion revascularization [TLR]).
Of 15,122 all-comer patients in the e-SELECT registry,
treatment of SmVD, deﬁned as at least one vessel with
estimated RVD≤ 2.5mm and excluding cases with un-
known RVD, was done in 4,700 patients (31%; 7,318
lesions; 8,443 stents), although treatment of NSmVD
only was performed in 10,139 patients (67%; 12,204
lesions; 14,508 stents); proportions of cases with mul-
tiple stents, approximately 19%, and of overlapped
stents amongmultiple-stent cases, approximately 87%,
were similar for both groups. There were 3,188 with
pure SmVD (RVD ≤ 2.5 mm only) and 1,795 with
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mixed SmVD (some vessel with RVD ≤ 2.5 mm or un-
known RVD, the latter amounting to 283 patients). In
the overall e-SELECT registry, 98.2% of patients were
eligible for follow-up at 12 months. Of these 92.0%
underwent follow-up at a mean follow-up of 370.4 ±
124.7 days. As previously reported for the e-SELECT
registry, at 1 year (the follow-up length), the reported
compliance with dual antiplatelet therapy (DAPT) as
recommended by the European Society of Cardiology
guidelines was 86.3%.27
Statistical Analysis. For all patients, standard de-
scriptive statistics were used for baseline, lesion,
and procedural characteristics and for clinical re-
sults. Continuous variables are presented as mean ±
SD and compared using the Student’s t-test, and
categorical variables are presented as numbers and
percentages and compared using the chi-square test.
Cumulative rates of adverse clinical events were calcu-
lated with event-speciﬁc adjusted denominators, there-
fore all patients experiencing an event within 360
days or followed up for at least 330 days after in-
dex procedure contributed to the denominator. There
was no censoring. MACE-free survival curves were
constructed by the Kaplan–Meier life-table method,
and compared by the log-rank test. Predictors of ma-
jor adverse cardiac events were identiﬁed by univariate
and multivariate analyses with Cox proportional haz-
ards model. The following baseline covariates with
>15% missing values were excluded from analysis:
creatine kinase-MB isoenzyme (CK-MB) or troponin
levels greater than upper limit of normal preprocedure;
hemoglobin level preprocedure; left ventricular ejec-
tion fraction (LVEF), maximum inﬂation pressure, and
platelet count. Baseline demographic, angiographic,
clinical, and procedural covariates were identiﬁed by
univariate analysis as signiﬁcantly correlated (P <
0.05) with MACE, namely Charlson Comorbidity In-
dex (CCI), saphenous vein graft (SVG)34 target le-
sion, MB, age, number of stents implanted, total stent
length, bifurcation lesion, in-stent restenosis (ISR)
target lesion, any deviation from continuous DAPT
up to 1-month follow-up, acute coronary syndrome
(ACS), diabetes mellitus (DM), insulin-dependent
DM (IDDM), MVD, maximum lesion length, index
procedure-related ST, previous CABG, bypass graft
lesion, chronic pulmonary disease, chronic Vitamin K
antagonists (AVK) treatment, total number of lesions
treated, major or minor bleeding, postdilation, moder-
ate to severe renal disease, multisent-treated patient,
diabetes with retinopathy, neuropathy or nephropa-
thy, multilesion-treated patient, calciﬁcation, history
of prior MI, ostial location, American College of Car-
diology/American Heart Association (ACC/AHA) le-
sion morphology class B2 or C, unprotected left main
target lesion, history of hyperlipidemia, and predilata-
tion. Following the rule of 20 events per predictor, 13
of themost clinicallymeaningful univariate parameters
with P< 0.05 (ﬁrst 13 in the aforementioned univariate
predictors) were included in the multivariate analysis.
All statistical analyses were performed with SAS (ver-
sion 9.1 or higher software, SAS Institute, Cary, NC,
USA).
Results
As shown in Table 1, the SmVD patient popula-
tion was older (63.2 years vs. 61.7 years, P < 0.001),
with a higher proportion of women (28.4% vs. 22.9%,
P < 0.001), diabetics (34.1% vs. 28.6%, P < 0.001),
and higher mean CCI (1.1 ± 1.4 vs. 1.0 ± 1.3, P
< 0.001) and had more vessels treated (1.3 vs. 1.1,
P < 0.001). Patients with SmVD presented less of-
ten with ST-segment Elevation Myocardial Infarction
(STEMI) (5.8% vs. 7.6%, P < 0.001), and had shorter
lesions (19.1 mm vs. 20.8 mm, P < 0.001). The rate
of ARC-deﬁned “deﬁnite or probable” ST was signif-
icantly higher in the SmVD group (1.3% vs. 0.7%,
P < 0.001), mainly driven by a higher incidence of
early (0–30 days) ST (0.9% vs. 0.4%, P = 0.002; Fig.
1). The incidence of MACE (any death, MI, or TLR,
5.4% vs. 4.0%, P < 0.001), MI (2.4% vs. 1.5%, P <
0.001), and clinically indicated TLR (2.7% vs. 1.8%, P
< 0.001) was signiﬁcantly higher at 1 year in patients
with SmVD, respectively (Fig. 2). TheMACE-free sur-
vival rate at 1 year was signiﬁcantly lower in SmVD
than that in NSmVD (Fig. 3). The incidence of death
(1.7% vs. 1.5%, P = 0. 287) and MB (1.0% vs. 0.8%,
P = 0.218) was similar in both groups. There was a nu-
merical trend of increasingMACE rate with decreasing
RVD (Fig. 4). The pure SmVD group had a higher pro-
portion of women (30.6% vs. 23.5%, P < 0.001), with
more prior PCI (33.1% vs. 30.1%, P = 0.028), higher
mean CCI (1.2 vs. 1.1, P = 0.026), more STEMI (6.5%
vs. 4.7%, P = 0.0119), fewer number of vessels or le-
sions treated (1.1 vs. 1.6, P < 0.001, and 1.2 vs. 2.3,
P < 0.001, respectively), and smaller RVD (2.4 mm
vs. 2.8 mm, P < 0.001). However, the MACE-free
survival rate at 1 year was not signiﬁcantly different
between the pure and mixed SmVD groups (Fig. 5);
the MACE-free survival rate at 1 year in the mixed
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Figure 1. Histogram representation of deﬁnite/probable stent thrombosis according to the ARC deﬁnitions comparing the
small-vessel disease and non-small-vessel disease subsets of the e-SELECT registry.
SmVD was signiﬁcantly lower than that in NSmVD
group (Fig. 6). The multivariate predictors for MACE
in the SmVD group at 1 year included SVG or bifur-
cation target lesions, MB, any deviation from continu-
ous DAPT up to 1-month follow-up, age [years], num-
ber of total stents implanted, CCI, ACS, and IDDM;
(Table 2). Stent overlap was not a univariate pre-
dictor for MACE at 1 year (Hazard Ratio (HR)
1.05, 95% Conﬁdence Interval (CI) 0.68–1.61,
P = 0.833).
Discussion
This study of one of the largest cohorts of SmVD
(≤2.5 mm estimated RVD) conﬁrms that SES implan-
tation for SmVD occurs more frequently in women,
diabetics, those with MVD, and comorbidities. Death
rate at 1 year is similar to that of patients with NSmVD,
and although incidence of MACE, MI, clinically indi-
cated TLR, and ST is higher in patients with SmVD,
and in those with mixed SmVD, it remains low over-
all. The proportion of SmVD treated in the e-SELECT
registry, 31%, is within the range of previously re-
ported ones in real-world interventional cardiology
studies.35 As further supported by this study, patients
with smaller vessels have higher frequency of several
characteristics, includingDMandMVD that have been
associated with a poorer outcome after stent implanta-
tion;1,36,38 smaller coronaries also are more common
in certain groups of patients including women and
Asians.19 The lower frequency of STEMI presentation
in the SmVD versus NSmVD group (5.8% vs. 7.6%,
P < 0.001) stands in contrast to a previous report37 on
a large cohort of 798 STEMI patients in whom approx-
imately 50% of culprit lesions were located in smaller
vessels (<3mm). The increased risk ofMACE in small
relative to large vessels has been seen in previous stud-
ies6–9 and in this study is mainly due to increased MI,
ST, and TLR rates in SmVD patients, although the
death rate is similar between the SmVD and NSmVD
groups. Despite the remarkably low values for late lu-
men loss documented in DES studies, there remains
a relationship between vessel size and restenosis, with
increased restenosis rates in smaller vessels; the same is
true for ST. Several studies, both randomized and non-
randomized, and subanalyses of all-comer studies have
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Figure 2. Major adverse clinical events at 1 year.
Figure 3. MACE-free survival curves at
1 year comparing patients with SmVD and
NSmVD.
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Figure 4. Correlation between MACE and RVD.
Figure 5. MACE-free survival curves at 1 year
comparing patients with pure and mixed SmVD.
supported better outcomes in small vessels with SES,
and in direct and indirect comparisons to PES.15,38–45
Although some interventionists support balloon-only
angioplasty for SmVD treatment,46,47 SES has shown
consistent beneﬁt and lower rates of complications than
alternative treatments12,38–40,42,48–51 even when using,
as was not the case in this study, 2.5 mm stents in
vessels with <2.5 mm diameter,40,44,52,53 or in patients
with diabetes and very small coronary vessel (<2.1
mm) disease,15 or even relative to thinner-strut bare
metal stents (BMS) or DES.17,54 In terms of the poten-
tial for improving outcomes of PCI in SmVD, studies
have shown that speciﬁc baseline clinical and angio-
graphic characteristics are predictive of the different
rates of MACE, including restenosis, seen for various
lesion/patient subsets.39 Diabetes, for instance, exacer-
bates the negative impact on outcomes of smaller vessel
size,39,55,56,57 and insulin treatment was a multivariate
predictor of in-segment restenosis in the Taxus in Real-
life Usage Evaluation (TRUE) registry.4 In this study
IDDM was identiﬁed as one of the multivariate pre-
dictors of 1-year MACE. Hausleiter et al.55 and Iijima
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Figure 6. MACE-free survival curves at 1 year comparing patients with mixed SmVD and NSmVD.
Table 1. Baseline Patient and Procedural Characteristics of the SmVD and NSmVD Groups
SmVD N = 4,700 NSmVD N = 10,139 P-value
Age (years) 63.2 ± 11 61.7 ± 11 <0.001
Male (%) 71.6 77.1 <0.001
Prior PCI (%) 32.4 32.2 0.86
Prior CABG (%) 10.7 8.3 <0.001
Prior MI (%) 31.6 32.6 0.23
Hypertension (%) 69.0 66.8 0.008
Hyperlipidemia (%) 70.8 67.3 <0.001
History of smoking (%) 51.0 54.8 <0.001
Diabetes mellitus (%) 34.1 28.6 <0.001
Insulin treated DM (%) 29.2 25.8 0.015
LVEF < 30% (%) 3.0 2.6 0.32
Charlson Comorbidity Index score 1.1 ± 1.4 1.0 ± 1.3 <0.001
STEMI (%) 5.8 7.6 <0.001
Number of vessels treated 1.3 ± 0.5 1.1 ± 0.4 <0.001
RVD (mm) 2.6 ± 0.4 3.1 ± 0.3 <0.001
Number of lesions treated 1.6 ± 0.8 1.2 ± 0.5 <0.001
Lesion length (mm) 19.0 ± 10.6 20.8 ± 12.0 <0.001
Number of stents/patient 1.8 ± 1.0 1.4 ± 0.7 <0.001
Number of stents/lesion 1.16 ± 0.42 1.19 ± 0.47 <0.001
Mean stent diameter (mm) 2.6 ± 0.2 3.1 ± 0.3 <0.001
Total stent length (mm)/lesion 24.2 ± 12.1 26.0 ± 13.7 <0.001
Lesions with predilatation (%) 67.5 62.3 <0.001
Stents with postdilatation (%) 33.1 37.8 <0.001
DAPT postprocedure (%) 97.1 97.3 0.33
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Table 2. Multivariate Predictors of MACE at 1 Year in the SmVD Group
Predictors of MACE to 360 days Multiple CoxPh regression Hazard ratio [95% CI] P-value
Charlson Comorbidity Index 1.11 [1.06–1.16] <0.001
SVG target lesion 3.63 [2.01–6.58] <0.001
Major bleeding 3.35 [1.69–6.63] <0.001
Age (years) 1.02 [1.01–1.03] 0.002
Number of stents implanted 1.20 [1.06–1.35] 0.003
Bifurcation lesion 1.55 [1.10–2.17] 0.011
Any deviation from continuous DAPT (up to 1-month follow-up) 2.26 [1.18–4.32] 0.014
ACS 1.38 [1.06–1.80] 0.016
Insulin-dependent diabetes mellitus 1.94 [1.05–3.60] 0.034
et al.57 identiﬁed total stent length as a predictor of
restenosis in SmVD treated with BMS; however, stent
length was not among multivariate predictors of in-
segment restenosis in a study of small vessel lesions
(<2.75 mm) treated with PES.4 In a Korean study
of 1,269 lesions in small coronaries (≤2.8 mm), le-
sion length was a powerful predictor of restenosis and
MACE, with multiple overlapping stents in very long
SmVD (lesion length ≥60 mm) being associated with
a high risk of SES failure.58 In this study total stent
number but not total stent length or stent overlap was a
multivariateMACE predictor in SmVD. The CCI score
which captures cardiovascular status is a MACE pre-
dictor as reported byHausleiter et al.55 which identiﬁed
ACS at admission and LVEF as predictors of early ad-
verse clinical outcomes in BMS-treated SmVD. Age
was a MACE predictor of MACE in this and another
report.10 As in this study, Iijima et al.57 identiﬁed bi-
furcation lesion as a MACE predictor. PCI of SVG is
associated with worse outcomes and high incidence of
ISR.5 The ﬁnding in this study that DAPT discontin-
uation during the ﬁrst month postindex procedure is a
predictor of 1-year MACE is consistent with previous
reports59 and underscores the importance of DAPT use
particularly during the ﬁrst month postindex proce-
dure; however, the ﬁnding that bleeding is also aMACE
predictor in SmVD PCI calls for caution in the use of
DES in the setting of patients at high risk for bleed-
ing. This study showed that the MACE-free survival
rate at 1 year was not signiﬁcantly different between
the pure and mixed SmVD groups; it was also signiﬁ-
cantly lower in mixed SmVD than in NSmVD which,
to our knowledge, has not been previously reported in
the literature. This ﬁnding has potential clinical signif-
icance. In clinical practice, patients with mixed vessel
size (combined RVD ≤ 2.5 mm and RVD > 2.5 mm)
are common, and to avoid unnecessarily increasing
MACE one needs to consider the severity of lesion
stenosis and the territory of ischemia of the SmVD
before treating the lesion.
This study is limited by the fact that the Cypher
stent has been withdrawn from markets in most coun-
tries; however, SES are extensively used inmany places
around the world, and the lessons learned from this
study may also be suitable for treatment of SmVD
with other limus-eluting stents. The study was an in-
ternational multicenter registry, and the inclusion and
exclusion criteria nonetheless allow for an analysis
with lessened confounding. Because of the extensive
multinational and multicenter nature of the registry
study, the RVD was visually estimated without quanti-
tative coronary angiography analysis, which does not
allow validation of the actual vessel sizes included in
the groups studied. However, the vessel size thresh-
old used is not uncommon and the majority of small
vessels treated were of similar estimated RVD, namely
2.5, as reﬂected by the standard deviation of 0.2. Also,
although follow-up was conducted for 1 year, which
does not address very late safety, i.e., events occurring
beyond 1 year, the results of this international mul-
ticenter large-cohort study of outcomes after PCI of
SmVD show favorable efﬁcacy and safety of SES im-
plantation in unselected patients and consistency with
previous similar smaller studies. Only unadjusted rates
of clinical events were compared between vessel size
groups because the emphasis was on comparative epi-
demiology of SmVDandoutcomepredictors.Analyses
also included pure and mixed SmVD groups which un-
derscored the ﬁndings with the overall SmVD cohort
(i.e., that including pure and mixed cases).
Conclusion
This large cohort study of SmVD conﬁrms that
SES implantation for SmVD occurs more frequently
in women, diabetics, and those with MVD and
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comorbidities. The incidence of MACE, MI, clini-
cally indicated TLR, and ST is higher in patients with
SmVD, whether pure or mixed SmVD, although it re-
mains low overall. Death rate at 1 year is similar be-
tweenSmVDandNSmVD.Themultivariate predictors
of 1-year MACE include SVG or bifurcation target le-
sions, MB, any deviation from continuous DAPT up to
1 month follow-up, age (years), number of total stents
implanted, CCI, ACS, and IDDM.
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